Open AccessNovel Treatment of Infant With COVID-19 With the Sialidase Fusion Protein, DAS181
Author(s) -
Lara DanzigerIsakov,
Nadim Khalil,
Allison Divanović,
Robert W. Frenck,
Michael Grimley,
Ilias Iliopoulos,
Rebecca Marsh,
Grant Paulsen,
Christine L Phillips,
Grant S. Schulert,
Paul Spearman,
Samantha Blum,
Jennifer Hui-Chin Ho
Publication year - 2021
Publication title -
the pediatric infectious disease journal/the pediatric infectious disease journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 140
eISSN - 1532-0987
pISSN - 0891-3668
DOI - 10.1097/inf.0000000000003122
Subject(s) - respiratory distress , covid-19 , medicine , coronavirus , antiviral therapy , rescue therapy , drug , antiviral drug , virology , respiratory system , intensive care medicine , disease , immunology , pharmacology , anesthesia , virus , infectious disease (medical specialty) , outbreak , chronic hepatitis
We describe the successful treatment of a 10-month-old female with respiratory distress secondary to Coronavirus disease 2019 (COVID-19) with the nebulized investigational drug, DAS181. Therapy was well tolerated, and the patient had minimal side effects. The patient's respiratory distress and positive viral polymerase chain reaction rapidly resolved after initiation of therapy.